齐拉西酮和利培酮治疗精神分裂症的临床疗效及安全性评价

发布时间：2018-04-01 19:36

本文选题：精神分裂症　切入点：齐拉西酮　出处：《健康之路》2018年01期

【摘要】：目的:探讨精神分裂症治疗中齐拉西酮、利培酮的效果及安全性。方法:抽取2015年5月至2017年1月我院收治的精神分裂症患者58例为研究对象,以临床治疗所用药物分组:29例采用利培酮者作为对照组,29例采用齐拉西酮者作为实验组,评估两组治疗效果,并观察药物副反应发生情况。结果:(1)实验组治疗总有效率与对照组无统计学差异(P0.05);(2)实验组副反应发生率显著低于对照组(P0.05)。结论:齐拉西酮、利培酮在精神分裂症治疗中的效果旗鼓相当,但前者安全性更高,故建议采用齐拉西酮治疗。
[Abstract]:Objective: to investigate the efficacy and safety of ziprasidone and risperidone in the treatment of schizophrenia. One hundred and twenty-nine patients with risperidone were divided into two groups: control group (n = 29) and ziprasidone group (n = 29). Results there was no significant difference in the total effective rate between the experimental group and the control group (P 0.05)) the incidence of side effects in the experimental group was significantly lower than that in the control group (P 0.05). Conclusion: the total effective rate of the experimental group was significantly lower than that of the control group. Risperidone is equally effective in the treatment of schizophrenia, but the former is more safe, so ziprasidone is recommended.
【作者单位】：深圳市龙岗区慢性病防治院;
【分类号】：R749.3

【相似文献】